Sized-based detection techniques for detection of bio-nanoparticles are described. Detection nanoparticles and methods of forming the detection nanoparticles that can be utilized in the techniques are described. Detection nanoparticles can include modified bacteriophage that express a linking agent for a specific binding agent. Detection nanoparticles can bind a functional bio-nanoparticle with high specificity through specific binding of one or more entities unique to the functional bio-nanoparticle of interest. A detection nanoparticle can target an entity of a bio-nanoparticle that is relevant to its function, and as such, the methods can provide improvements in detection of complete and functional bio-nanoparticles. Size-based detection regimes can include particle displacement measurement techniques based upon Brownian motion.

Sized-based detection techniques for detection of bio-nanoparticles are described. Detection nanoparticles and methods of forming the detection nanoparticles that can be utilized in the techniques are described. Detection nanoparticles can include modified bacteriophage that express a linking agent for a specific binding agent. Detection nanoparticles can bind a functional bio-nanoparticle with high specificity through specific binding of one or more entities unique to the functional bio-nanoparticle of interest. A detection nanoparticle can target an entity of a bio-nanoparticle that is relevant to its function, and as such, the methods can provide improvements in detection of complete and functional bio-nanoparticles. Size-based detection regimes can include particle displacement measurement techniques based upon Brownian motion.

The present invention relates to a nanoplasmonic biosensor capable of label-free multiplex detection of disease markers in blood with high selectivity and sensitivity and a method for detecting disease markers using the nanoplasmonic biosensor. The nanoplasmonic biosensor of the present invention enables label-free multiplex detection of miRNAs as disease markers in blood with high selectivity and sensitivity. Therefore, the nanoplasmonic biosensor of the present invention can be effectively used for the diagnosis of miRNA-related diseases and clinical applications.

The present invention relates to a nanoplasmonic biosensor capable of label-free multiplex detection of disease markers in blood with high selectivity and sensitivity and a method for detecting disease markers using the nanoplasmonic biosensor. The nanoplasmonic biosensor of the present invention enables label-free multiplex detection of miRNAs as disease markers in blood with high selectivity and sensitivity. Therefore, the nanoplasmonic biosensor of the present invention can be effectively used for the diagnosis of miRNA-related diseases and clinical applications.

Provided herein are encoded microcarriers for analyte detection in multiplex assays. The microcarriers are encoded with an analog code for identification and include a capture agent for analyte detection. Also provided are methods of making the encoded microcarriers disclosed herein. Further provided are methods and kits for conducting a multiplex assay using the microcarriers described herein.

Provided herein are encoded microcarriers for analyte detection in multiplex assays. The microcarriers are encoded with an analog code for identification and include a capture agent for analyte detection. Also provided are methods of making the encoded microcarriers disclosed herein. Further provided are methods and kits for conducting a multiplex assay using the microcarriers described herein.

An embodiment of a system includes a compartment-generating device, a compartment detector, and electronic computing circuitry. The device is configured to generate compartments of a digital assay, at least one of the compartments having a respective volume that is different from a respective volume of each of at least another one of the compartments. The detector is configured to determine a number of the compartments each having a respective number of a target that is greater than a threshold number of the target. And the electronic circuitry is configured to determine a bulk concentration of the target in a source of the sample in response to the determined number of compartments. Because such a system can be configured to estimate a bulk concentration of a target in a source from a polydisperse digital assay, the system can be portable, and lower-cost and faster, than conventional systems.

An embodiment of a system includes a compartment-generating device, a compartment detector, and electronic computing circuitry. The device is configured to generate compartments of a digital assay, at least one of the compartments having a respective volume that is different from a respective volume of each of at least another one of the compartments. The detector is configured to determine a number of the compartments each having a respective number of a target that is greater than a threshold number of the target. And the electronic circuitry is configured to determine a bulk concentration of the target in a source of the sample in response to the determined number of compartments. Because such a system can be configured to estimate a bulk concentration of a target in a source from a polydisperse digital assay, the system can be portable, and lower-cost and faster, than conventional systems.

Disclosed are probes, primers, a microarray, a kit and applications for rapid detection of clinical microorganism in ophthalmology, belonging to that technical field of clinical microorganism detection. The probes of that disclosure comprise probes for respectively detect Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus haemolyticus, Pseudomonas aeruginosa, Staphylococcus hominis, Serratia marcescens, Escherichia coli, Bacillus subtilis and Enterobacter cloacae. The disclosure also discloses primers for amplifying the target bacteria, which comprises primers which can amplify gene sequence fragments with intra-species homology of more than 95 percent (%) and inter-species homology of less than 75%. The disclosure also provides a method for synthesizing the hybridization probe on the microarray, a method for hybridization reaction and a method for scanning detection. The probes described in the present invention are highly specific and detects microorganisms in ophthalmic clinical samples with sufficient positivity, high accuracy and deliver diagnosis in a short period of time.

Provided herein are nucleic acid-cleaving catalytic nucleic acid probes, biosensors and lateral flow biosensor devices and methods and kits of using the probes, biosensors and lateral flow biosensor devices for detecting an analyte present on or generated from a microorganism in a test sample, including Helicobacter pylori and methods for determining whether a subject has a Helicobacter pylori infection.